[KJ-INT-002] BE Study
NCT03509831
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
37
Enrollment
OTHER
Sponsor class
Conditions
Gastritis
Interventions
DRUG:
INT-2150
DRUG:
Irsogladine maleate 2 mg+Nizatidine 150 mg
Sponsor
Kukje Pharma